Sudarshan Pharma

  • Market Cap: Micro Cap
  • Industry: Specialty Chemicals
  • ISIN: INE00TV01023
  • NSEID:
  • BSEID: 543828
INR
26.20
-0.44 (-1.65%)
BSENSE

Dec 05

BSE+NSE Vol: 24000

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Nitta Gelatin
Valiant Organics
DMCC Speciality
Sudarshan Pharma
Nikhil Adhesives
Black Rose Indus
Kronox Lab
Jayant Agro Org.
Chemcon Special.
Bhatia Colour
Sacheerome
Why is Sudarshan Pharma Industries Ltd ?
1
Flat results in Sep 25
  • PBT LESS OI(Q) At Rs 2.74 cr has Fallen at -42.8% (vs previous 4Q average)
  • NON-OPERATING INCOME(Q) is 43.27 % of Profit Before Tax (PBT)
2
Below par performance in long term as well as near term
  • Along with generating -36.65% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Specialty Chemicals)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sudarshan Pharma for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Sudarshan Pharma
-36.42%
-0.84
43.81%
Sensex
4.41%
0.45
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
27.70%
EBIT Growth (5y)
51.12%
EBIT to Interest (avg)
2.42
Debt to EBITDA (avg)
5.22
Net Debt to Equity (avg)
1.54
Sales to Capital Employed (avg)
1.53
Tax Ratio
25.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.84%
ROCE (avg)
10.65%
ROE (avg)
12.34%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
40
Industry P/E
34
Price to Book Value
4.62
EV to EBIT
24.52
EV to EBITDA
22.76
EV to Capital Employed
2.43
EV to Sales
1.70
PEG Ratio
0.95
Dividend Yield
NA
ROCE (Latest)
9.90%
ROE (Latest)
11.61%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
OPERATING CF(Y)

Highest at Rs 34.91 Cr

NET SALES(Q)

Highest at Rs 167.01 cr

EPS(Q)

Highest at Rs 1.83

-4What is not working for the Company
PBT LESS OI(Q)

At Rs 2.74 cr has Fallen at -42.8% (vs previous 4Q average

NON-OPERATING INCOME(Q)

is 43.27 % of Profit Before Tax (PBT

Loading Valuation Snapshot...
Here's what is working for Sudarshan Pharma
Operating Cash Flow - Annually
Highest at Rs 34.91 Cr and Grown
each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Net Sales - Quarterly
Highest at Rs 167.01 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 167.01 cr has Grown at 26.2% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 132.31 Cr
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 1.83
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Sudarshan Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 2.74 cr has Fallen at -42.8% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 4.79 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Non Operating Income - Quarterly
is 43.27 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT